News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BioTime (BTX) To Collaborate With The University of Wisconsin And Louvain University In Test Of Hystem®-Based Hydrogel For Vocal Fold Scarring



8/28/2014 10:23:31 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT:BTX) today announced that it has entered into a collaboration with Susan Thibeault, Ph.D., of the University of Wisconsin and Marc Remacle, M.D. of Louvain University to evaluate BioTime’s proprietary HyStem®-based hydrogel for the treatment of vocal fold scarring. Preclinical studies published by Dr. Thibeault and her colleagues have demonstrated that localized delivery of HyStem® into injured vocal folds resulted in a significant improvement in function. Under a sponsored research agreement, Dr. Thibeault’s laboratory will evaluate HyStem®-based hydrogels to identify formulations with optimum properties for reducing scarring. Upon completion of these preclinical studies, an investigator-initiated clinical trial in patients with vocal fold scarring due to disease or prior surgical interventions is planned, under the direction of Dr. Remacle, at the Cliniques Universitaires UCL Mont-Godinne in Belgium, subject to institutional and regulatory approval.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES